Marie Tatt wrote a letter to Elias Greene (and others) about the product licence application for Koate HS and requested that the existing "Warnings" statement (used in US markets) be amended for the UK. She wrote: "we would like to delete the reference to the Fletcher paper and potential transmission of Non-A, Non-B hepatitis". Read more about Marie Tatt wrote a letter to Elias Greene (and others) about the product licence application for Koate HS and requested that the existing "Warnings" statement (used in US markets) be amended for the UK. She wrote: "we would like to delete the reference to the Fletcher paper and potential transmission of Non-A, Non-B hepatitis".
A report of the Meeting of Blood Products Advisory Committee on the Safety and Purity of Plasma Derivatives records that Dr Rodell warned that one donor infected with AIDS may make several contributions. He suggested that as few as four donors infected with AIDS could infect the whole world supply of factor concentrate. Read more about A report of the Meeting of Blood Products Advisory Committee on the Safety and Purity of Plasma Derivatives records that Dr Rodell warned that one donor infected with AIDS may make several contributions. He suggested that as few as four donors infected with AIDS could infect the whole world supply of factor concentrate.
Roderick Murray wrote the article "Viral Hepatitis", published in the Bulletin of the New York Academy of Medicine, which established that increasing pool sizes did not have the effect of dilution (and that any infectious particles would infect the whole pool). Read more about Roderick Murray wrote the article "Viral Hepatitis", published in the Bulletin of the New York Academy of Medicine, which established that increasing pool sizes did not have the effect of dilution (and that any infectious particles would infect the whole pool).
Dr John Craske's article "An Outbreak of Hepatitis Associated with Intravenous Injection of Factor-VIII Concentrate" was published in The Lancet. It said: "Testing the pooled plasma or the factor-VIII concentrate by the current radioimmunoassay techniques is not a reliable method of excluding hepatitis-B virus. Individual donations should be screened by R.I.A. before being pooled." Read more about Dr John Craske's article "An Outbreak of Hepatitis Associated with Intravenous Injection of Factor-VIII Concentrate" was published in The Lancet. It said: "Testing the pooled plasma or the factor-VIII concentrate by the current radioimmunoassay techniques is not a reliable method of excluding hepatitis-B virus. Individual donations should be screened by R.I.A. before being pooled."
Hepatitis B tests were not sufficiently sensitive to detect every infected unit for over a decade after screening first became available. Read more about Hepatitis B tests were not sufficiently sensitive to detect every infected unit for over a decade after screening first became available.
At an NIBSC Infectious Hazards of Blood Products meeting Dr Rodell gave a summary of the commercial pool sizes and stated that one donor probably would not contribute more than four units to a particular pool. Read more about At an NIBSC Infectious Hazards of Blood Products meeting Dr Rodell gave a summary of the commercial pool sizes and stated that one donor probably would not contribute more than four units to a particular pool.
The draft label provided with the product licence application for heat-treated Kryobulin did not give a donor pool size figure. Read more about The draft label provided with the product licence application for heat-treated Kryobulin did not give a donor pool size figure.
The figure of 1,000 donors appeared on a draft product label for Prothromplex. Read more about The figure of 1,000 donors appeared on a draft product label for Prothromplex.
The figure of 1,000 donors appeared on a product label for Kryobulin Red (made with European plasma) in the mid 1970s. Read more about The figure of 1,000 donors appeared on a product label for Kryobulin Red (made with European plasma) in the mid 1970s.
A report included in the initial product licence application for Kryobulin by Serological Products Ltd recorded that the pool size used was 1,000 donors between the ages of 18 and 65, whose plasma was obtained from centres in Austria and West Germany. Read more about A report included in the initial product licence application for Kryobulin by Serological Products Ltd recorded that the pool size used was 1,000 donors between the ages of 18 and 65, whose plasma was obtained from centres in Austria and West Germany.